Hale David F's Form 4 filing
Oncternal Therapeutics, Inc. (ONCT) · filed Feb 27, 2024
- Accession no.
- 0001209191-24-004016
- Filed
- Feb 27, 2024
- Trade date
- Feb 23, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $8.86K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hale David FCIK 0001024004 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024.
Referenced by the price of 2 transactions in Table I.
Remarks
The number of shares of common stock in this form have been adjusted to reflect the Issuer's 1-for-20 reverse stock split effective as of January 8, 2024.